New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1231-1237

  Itoh, Yukoh ^a   Komohara, Yoshihiro ^b   Komatsu, Nobukazu ^a   Minami, Takafumi ^c   Saito, Koujiro ^a   Noguchi, Masanori ^a   Itoh, Kyogo ^a   Harada, Mamoru ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocytes; Enhancer of zeste homolog 2; Human leukocyte antigen A2; Peptide; Prostate cancer

Indexed keywords

DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; HLA A2 ANTIGEN; PEPTIDE FRAGMENT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; COLD; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY; PROSTATE TUMOR;

CD8-POSITIVE T-LYMPHOCYTES; COLD; DNA-BINDING PROTEINS; HLA-A2 ANTIGEN; HUMANS; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS;

EID: 38449092299     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.5.1231     Document Type: Article

References (23)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics 2000. CA Cancer J Clin 50: 7-33, 2000.
2. Harada M, Noguchi M and Itoh K: Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 8: 193-199, 2003. (Pubitemid 37122253)
3. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G and Rivoltini L: Vaccination therapy in prostate cancer. Cancer Immunol Immunother 56: 429-445, 2007. (Pubitemid 46204530)
4. Varambally S, Dhanasekaran SM, Zhou M, Barrette TB, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Oyye AP, Rubin MA and Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
5. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L and Jenuwein T: Mammalian homologue of the Polycomb-group gene Enhancer of zeste mediates gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16: 3219-3232, 1997. (Pubitemid 27234960)
6. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003. (Pubitemid 37205983)
7. Jacobs JJ, Kieboom K, Mario S, DePinho RA and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168, 1999. (Pubitemid 29050921)
8. Jacob JJ, Scheijen B, Voncken JW, Kieboom K, Berns A and van Lohuizen M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13: 2678-2690, 1999. (Pubitemid 29508555)
9. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, van Eynde A, Bernard D, van der Winden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y and Fuks F: The polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006. (Pubitemid 43255707)
10. Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH and Young LS: The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95: 1202-1211, 2006. (Pubitemid 44658484)
11. Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K and Harada M: Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 60: 273-281, 2004. (Pubitemid 39050645)
12. Imanishi T, Akazawa T and Kimura A: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991. Tsuji K, Aizawa M and Sasazuki T (eds). Vol. 1. Oxford Scientific Publications, Oxford, pp1065-1220, 1992.
13. + patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 53: 479-489, 2004.
14. Parker KC, Bednarek MA and Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-175, 1994.
15. Komatsu N, Shichijo S, Nakagawa M and Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64: 1-11, 2004.
16. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A new culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228, 2002. (Pubitemid 34493956)
17. Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M and Itoh K: Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 57: 152-159, 2003. (Pubitemid 37204496)
18. Kobayashi K, Noguchi M, Itoh K and Harada M: Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 94: 622-627, 2003. (Pubitemid 36975018)
19. Kawamoto N, Yamada A, Ohkouchi S, Maeda T, Tanaka S, Hashimoto T, Saijo Y, Saijo S, Nukiwa T, Shichijo S, Aizawa H and Itoh K: IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients. Tissue Antigens 61: 352-361, 2003. (Pubitemid 36605668)
20. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K and Yamana H: Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94: 548-556, 2003. (Pubitemid 36849721)
21. Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K and Todo S: Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808, 2003. (Pubitemid 37258779)
22. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K and Kamura T: Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 27: 60-72, 2004. (Pubitemid 38076169)
23. + T cells reactive to a class I tumor peptide. J Immunol 172: 2659-2667, 2004. for Medical Science